Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Liver and Pancreas Tumors
•
Cholangiocarcinoma
•
Gastric/GEJ Cancer
For metastatic cholangiocarcinoma that has progressed on first line chemotherapy and immunotherapy, that is HER2 3+, which HER2 regimen is preferred, TDxD, Zanidatamab or tucatinib/trastuzumab?
Related Questions
How would active Crohn's on Adalimumab affect the adjuvant management of a T2aN0M0 gallbladder cancer?
In patients with perihilar cholangiocarcinoma eligible for liver transplant, what is the protocol for neoadjuvant chemo-RT, particularly when brachytherapy is not available?
Are durva/cis/gem or pembro/cis/gem less efficacious in cholangiocarcinomas with FGFR2 fusions?
How do you sequence hypofractionated radiation and systemic therapy for patients with unresectable cholangiocarcinoma?
How would you manage a solitary unresectable liver metastasis?
Would you offer zolbetuximab + chemotherapy in a presumed metastatic duodenal bulb adenocarcinoma with 80% Claudin18.2 expression?
What factors (age, PS) do you consider to avoid using FLOT in the perioperative treatment of gastric and esophageal cancers?
How are you sequencing immunotherapy with zolbetuximab in locally advanced/metastatic GEJ cancer when CPS >5 and Claudin 18.2+ (>75%)?
Would you still offer adjuvant chemo at 24 weeks post Whipple for a pT1c pN2 cM0 neg margins ampullary adenocarcinoma?
Would you ever consider using durvalumab/tremelimumab in second line after progression on Atezolizumab and Bevacizumab in advanced HCC?
